
SCYNEXIS SCYX
€ 2.94
-14.03%
Land |
|
IPO-Jahr |
2014 |
Branche |
Arzneimittelhersteller |
Börse |
NASDAQ GLOBAL |
Anteile |
49.9 M |
Marktkapitalisierung |
$ 165 M |
EBITDA (LTM) |
$ -24 M |
P/E (LTM) |
1.230483 |
P/S (LTM) |
8.022887 |
EPS (LTM) |
2.69 |
Andere Aktien der Branche "Arzneimittelhersteller"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | Nasdaq Capital Market | ||
|
Avadel Pharmaceuticals plc
AVDL
|
- | - | $ 2.06 B | Nasdaq Global Select Market | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | Nasdaq Capital Market | ||
|
Perrigo Company plc
PRGO
|
$ 15.7 | -2.08 % | $ 2.17 B | NYSE | ||
|
Rockwell Medical
RMTI
|
$ 7.7 | -4.35 % | $ 277 M | Nasdaq Global Market | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | Nasdaq Global Market,SPB | ||
|
Solid Biosciences
SLDB
|
$ 6.16 | -5.6 % | $ 539 M | Nasdaq Global Select Market,SPB | ||
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | Nasdaq Global Market | ||
|
Tilray
TLRY
|
$ 2.82 | -4.9 % | $ 315 M | Nasdaq Global Select Market | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | Nasdaq Capital Market | ||
|
Harrow Health
HROW
|
$ 26.0 | -9.57 % | $ 956 M | Nasdaq Global Market | ||
|
China Pharma Holdings
CPHI
|
$ 0.55 | -7.05 % | $ 2.36 M | NYSE American | ||
|
Veru
VERU
|
$ 2.06 | -6.36 % | $ 30.2 M | Nasdaq Capital Market | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | NYSE | ||
|
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | Nasdaq Global Market,SPB | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | Nasdaq Global Market,SPB | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | Nasdaq Global Select Market,SPB | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | Nasdaq Global Select Market,SPB | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | Nasdaq Capital Market | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | Nasdaq Global Select Market | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | Nasdaq Capital Market | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | NYSE,SPB | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | Nasdaq Global Select Market,SPB | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | Nasdaq Global Select Market | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | Nasdaq Global Market | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | Nasdaq Global Select Market | ||
|
Canopy Growth Corporation
CGC
|
$ 0.68 | -9.8 % | $ 203 M | Nasdaq Global Select Market | ||
|
Viatris
VTRS
|
$ 18.98 | -1.51 % | $ 21.7 B | Nasdaq Global Select Market,SPB | ||
|
cbdMD
YCBD
|
$ 0.39 | -2.6 % | $ 1.57 M | NYSE American | ||
|
Aurora Cannabis
ACB
|
$ 5.18 | -1.24 % | $ 284 M | NYSE | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 5.02 | 13.06 % | $ 74.6 M | Nasdaq Global Select Market | ||
|
Relmada Therapeutics
RLMD
|
$ 3.75 | -10.07 % | $ 148 M | Nasdaq Global Select Market,SPB | ||
|
Emergent BioSolutions
EBS
|
$ 5.87 | -0.51 % | $ 314 M | NYSE,SPB | ||
|
Cronos Group
CRON
|
$ 3.71 | 5.56 % | $ 1.42 B | Nasdaq Global Market | ||
|
Evolus
EOLS
|
$ 6.81 | -8.9 % | $ 439 M | Nasdaq Global Market | ||
|
Organogenesis Holdings
ORGO
|
$ 0.85 | -2.79 % | $ 108 M | Nasdaq Capital Market | ||
|
Bausch Health Companies
BHC
|
$ 7.97 | -4.49 % | $ 2.96 B | NYSE | ||
|
OrganiGram Holdings
OGI
|
$ 0.93 | -3.91 % | $ 88.6 M | Nasdaq Global Select Market | ||
|
Pacira BioSciences
PCRX
|
$ 36.43 | 0.08 % | $ 1.62 B | Nasdaq Global Select Market,SPB | ||
|
Sundial Growers
SNDL
|
$ 1.37 | -2.84 % | $ 354 M | Nasdaq Global Select Market | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | NYSE | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | Nasdaq Global Select Market | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 1.08 | -3.19 % | $ 1.82 M | Nasdaq Capital Market | ||
|
TherapeuticsMD
TXMD
|
$ 1.73 | -4.95 % | $ 20 M | Nasdaq Global Select Market | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | Nasdaq Global Market | ||
|
Assertio Holdings
ASRT
|
- | - | $ 150 M | Nasdaq Capital Market | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | Nasdaq Global Select Market | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Nasdaq Global Select Market | ||
|
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | Nasdaq Capital Market |